Related Experiment Video

Updated: May 19, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

KASL Clinical Practice Guidelines: Management of chronic hepatitis B

    Clinical and Molecular Hepatology
    |August 16, 2012
    PubMed

    Insights

    This guideline provides updated strategies for managing chronic hepatitis B (CHB), incorporating new antiviral treatments and addressing antiviral resistance. It offers evidence-based recommendations for diverse patient populations, including special circumstances.

    Area of Science:

    • Hepatology
    • Infectious Diseases
    • Clinical Practice Guidelines

    Background:

    • The Korean Association for the Study of the Liver (KASL) previously issued CHB management guidelines in 2004 and 2007.
    • Significant advancements in antiviral therapies and research, particularly concerning antiviral resistance in Korea, necessitate guideline updates.
    • New evidence and expert consensus have emerged since the last revision.

    Purpose of the Study:

    • To present a revised guideline for the management of chronic hepatitis B (CHB).
    • To incorporate recent scientific evidence and expert opinions into clinical practice recommendations.
    • To address the growing issue of antiviral resistance in CHB management.

    Main Methods:

    • Development of the guideline based on current evidence and expert consensus.
    • Review of recent research findings from Korea and internationally.
    • Consideration of specific patient populations and clinical scenarios.

    Main Results:

    • The guideline targets newly diagnosed and existing CHB patients.
    • It provides management guidance for special circumstances including malignancy, transplantation, dialysis, viral coinfections, pregnancy, and pediatric cases.
    • Focus on strategies to combat antiviral resistance.

    Conclusions:

    • The updated KASL guideline offers comprehensive, evidence-based recommendations for CHB management.
    • It emphasizes updated strategies for antiviral therapy and resistance.
    • Aims to improve patient outcomes in diverse clinical settings.
    Abstract

    Keywords:
    Chronic hepatitis BKASL guidelinesManagement

    Related Concept Videos

    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
    Cirrhosis I: Introduction01:23

    Cirrhosis I: Introduction

    Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
    Esophageal Varices-II: Clinical Features and Management01:28

    Esophageal Varices-II: Clinical Features and Management

    Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
    In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
    Viral Hepatitis I: Introduction01:28

    Viral Hepatitis I: Introduction

    Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
    Acute Pancreatitis II: Clinical Manifestations and Management01:30

    Acute Pancreatitis II: Clinical Manifestations and Management

    Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...